Anti-CYP2C19 antibody [EPR6576] (ab137015)

Rabbit Recombinant Monoclonal CP2CJ antibody. Suitable for WB, IHC-P and reacts with Mouse, Rat, Human samples. Cited in 16 publications.

Be the first to review this product! Submit a review

Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C19 antibody [EPR6576] (AB137015), expandable thumbnail

Publications

Key facts

Isotype: IgG
Host species: Rabbit
Storage buffer: pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Form: Liquid
Clonality: Monoclonal

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application

Product promiseTestedExpectedPredictedNot recommended

	WB	IHC-P
Human	Tested	Tested
Mouse	Tested	Tested
Rat	Tested	Tested

Tested
Tested

Species	Dilution info	Notes
Species Mouse	Dilution info 1/1000 - 1/10000	Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Species Rat	Dilution info 1/1000 - 1/10000	Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Species Human	Dilution info 1/1000 - 1/10000	Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Tested
Tested

Species	Dilution info	Notes
Species Mouse	Dilution info 1/1000	Notes For unpurified use at 1/250 - 1/500 Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Species Rat	Dilution info 1/1000	Notes For unpurified use at 1/250 - 1/500 Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Species Human	Dilution info 1/1000	Notes For unpurified use at 1/250 - 1/500 Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Target data

See full target information CYP2C19

Function

A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA) (PubMed:18577768, PubMed:19965576, PubMed:20972997). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18577768, PubMed:19965576, PubMed:20972997). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates PUFA specifically at the omega-1 position (PubMed:18577768). Catalyzes the epoxidation of double bonds of PUFA (PubMed:19965576, PubMed:20972997). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Hydroxylates fenbendazole at the 4' position (PubMed:23959307).

Alternative names

Cytochrome P450 2C19, (R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, CYPIIC17, CYPIIC19, Cytochrome P450-11A, Cytochrome P450-254C, Fenbendazole monooxygenase (4'-hydroxylating), Mephenytoin 4-hydroxylase, CYP2C19

Recommended products

Rabbit Recombinant Monoclonal CP2CJ antibody. Suitable for WB, IHC-P and reacts with Mouse, Rat, Human samples. Cited in 16 publications.

Key facts

Isotype: IgG
Host species: Rabbit
Storage buffer: pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Form: Liquid
Clonality: Monoclonal
Immunogen: The exact immunogen used to generate this antibody is proprietary information.
Clone number: EPR6576
Purification technique: Affinity purification Protein A
Specificity: This antibody is very likely to be cross-reactive with many Cytochrome P450 family members. According to the blast result, in human species, the immunogen has 100% homology with CYP2C9, CYP2A6 and CYP2A7, 85.7% with CYP2C18, 78.6% with CYP2A13 and CYP2C8. CYP2C19 doesn`t exist in mouse and rat species. The immunogen shares 100% homology with mouse CYP2A4, CYP2A5, CYP2A12, CYP2C29, CYP2C70 and rat CYP2A3, CYP2C6, CYP2C55, 92.9% with mouse CYP2C37, CYP2C50, CYP2C55 and rat CYP2C11, CYP2C13.
Dissociation constant: 1.24 x 10^-10 M
Concentration

Storage

Shipped at conditions: Blue Ice
Appropriate short-term storage duration: 1-2 weeks
Appropriate short-term storage conditions: +4°C
Appropriate long-term storage conditions: -20°C
Aliquoting information: Upon delivery aliquot
Storage information: Avoid freeze / thaw cycle

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

CYP2C19 also referred to as cytochrome P450 2C19 is an enzyme that belongs to the cytochrome P450 superfamily. This protein has a molecular mass of approximately 56 kDa. CYP2C19 is primarily expressed in the liver but also appears in the intestine. The enzyme plays a significant mechanical role in the oxidative metabolism of various substrates including both endogenous compounds and exogenous drugs. The chemical reactions it facilitates involve the oxidation of organic substances.

Biological function summary

Cytochrome P450 2C19 is responsible for metabolizing drugs such as proton pump inhibitors antiepileptic drugs and some antidepressants. This enzyme is part of a larger enzyme family that contributes to the detoxification processes and biosynthesis of steroid hormones. It acts by catalyzing the oxidative transformation of compounds which influences drug activation and clearance. Its substrate specificity includes many significant pharmacological agents.

Pathways

CYP2C19 is integrally involved in drug metabolism pathways particularly the Phase I metabolism. It cooperates with enzymes like CYP2C9 and CYP3A4 within these pathways performing hydrolytic and oxidative reactions that transform lipophilic drugs into more water-soluble derivatives. Consequently this activity prepares compounds for further modification in Phase II metabolism facilitating excretion from the body.

Associated diseases and disorders

CYP2C19 is implicated in conditions such as cardiovascular disease and adverse drug reactions. Genetic polymorphisms within the CYP2C19 gene lead to varied metabolic capacities affecting the efficacy and safety of therapeutics especially antiplatelet drugs like clopidogrel. Additionally alterations in CYP2C19 activity are associated with altered drug metabolism which may result in interactions with proteins such as P-glycoprotein and other cytochrome P450 enzymes affecting therapeutic outcomes.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

9 product images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C19 antibody [EPR6576] (ab137015)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Rat liver tissue sections labeling CYP2C19 with Purified ab137015 at 1:1000 dilution (0.49 μg/ml). Heat mediated antigen retrieval was performed using Antigen Retrieval Buffer (100X Tris-EDTA Buffer, pH 9.0) ab93684 (Tris/EDTA buffer, pH 9.0) ImmunoHistoProbe one step HRP Polymer (ready to use)was used as the secondary antibody. Negative control:PBS instead of the primary antibody. Hematoxylinwas used as a counterstain.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C19 antibody [EPR6576] (ab137015)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Mouse liver tissue sections labeling CYP2C19 with Purified ab137015 at 1:1000 dilution (0.49 μg/ml). Heat mediated antigen retrieval was performed using Antigen Retrieval Buffer (100X Tris-EDTA Buffer, pH 9.0) ab93684 (Tris/EDTA buffer, pH 9.0) ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control:PBS instead of the primary antibody. Hematoxylinwas used as a counterstain.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C19 antibody [EPR6576] (ab137015)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human liver tissue sections labeling CYP2C19 with Purified ab137015 at 1:1000 dilution (0.49 μg/ml). Heat mediated antigen retrieval was performed using Antigen Retrieval Buffer (100X Tris-EDTA Buffer, pH 9.0) ab93684 (Tris/EDTA buffer, pH 9.0) ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control:PBS instead of the primary antibody. Hematoxylinwas used as a counterstain.
Western blot - Anti-CYP2C19 antibody [EPR6576] (ab137015)
Blocking and diluting buffer: 5% NFDM/TBST.
All lanes: Western blot - Anti-CYP2C19 antibody [EPR6576] (ab137015) at 0.5 µg/mL
Lane 1: Mouse liver lysates at 15 µg
Lane 2: Rat liver lysates at 15 µg
Secondary
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 56 kDa
Western blot - Anti-CYP2C19 antibody [EPR6576] (ab137015)
Blocking and diluting buffer: 5% NFDM/TBST.
The doublet should be due to the cross-reaction with family members.

All lanes: Western blot - Anti-CYP2C19 antibody [EPR6576] (ab137015) at 0.5 µg/mL
Lane 1: Human fetal liver lysates at 15 µg
Lane 2: HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysates, negative control at 15 µg
Secondary
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 56 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C19 antibody [EPR6576] (ab137015)
Immunohistochemical analysis of paraffin-embedded Human liver tissue labelling CYP2C19 with unpurified ab137015 at 1/250 dilution.
Western blot - Anti-CYP2C19 antibody [EPR6576] (ab137015)
All lanes: Western blot - Anti-CYP2C19 antibody [EPR6576] (ab137015) at 1/1000 dilution
Lane 1: Mouse liver lysate at 10 µg
Lane 2: Rat liver lysate at 10 µg
Secondary
All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 56 kDa
OI-RD Scanning - Anti-CYP2C19 antibody [EPR6576] (ab137015)
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody.
Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
Image collected and cropped by CiteAb under a CC-BY license from the publication
Western blot - Anti-CYP2C19 antibody [EPR6576] (ab137015)
CYP2C19 western blot using anti-CYP2C19 antibody [EPR6576] ab137015. Publication image and figure legend from Grant, M. K. O., Abdelgawad, I. Y., et al., 2020, Int J Mol Sci, PubMed 32074957.

ab137015 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab137015 please see the product overview.
Effect of DOX treatment on the expression of the Cyp2c sub-family in the liver. Livers were collected from male or female C57Bl/6 mice 24 or 72 h following the administration of a single intraperitoneal injection of 20 mg/kg DOX or saline, and total proteins and RNA were isolated. (A) Gene expression of Cyp2c29 was determined by real-time PCR (n = 8 per group) and (B) protein levels of total Cyp2c were determined by western blot (n = 4 per group) in samples collected 24 h following DOX treatment. (C) Gene expression of Cyp2c29 (n = 4–5 per group) and (D) protein levels of Cyp2c (n = 4–5 per group) were determined in samples collected 72 h following DOX treatment. PCR results were normalized to beta-actin, and protein expression was normalized to alpha-tubulin. Results of all groups are expressed relative to the male control. Data are presented as the mean ± SEM. * p < 0.05, compared to control mice of the same sex; # p < 0.05, compared to male DOX-treated mice.